Research Fellow | Dermatology - Cutaneous Lymphoma
Job ID: 13547
Job Title: Research Fellow - Dermatology
Position Summary and Key Responsibilities:
The Division of Dermatology at City of Hope is offering a 2-year fellowship in cutaneous lymphoma. The position will provide a unique and broad experience and will include leadership roles in patient care, clinical trials, and various research projects. Working under the supervision of the Director of the Cutaneous Lymphoma Program, the fellow will collaborate with personnel from hematopoietic stem cell transplantation, medical oncology, pathology, and radiation oncology within a clinical and laboratory environment. Graduates from U.S. accredited medical schools are eligible to apply. Preference will be given to those who have completed a residency in internal medicine or dermatology and wish to pursue an academic career and/or dermatologic training. Applicants who have completed their internship year and have yet to undergo a formal residency are also encouraged to apply.
Minimum Education and Skills Required for Consideration:
- MD orPh.D. degree in related discipline is required (MD preferred)
- Must have excellent written and verbal communication skills
Required Items for Consideration
About Querfeld Laboratory
Christiane Querfeld, M.D., Ph.D., director of the Cutaneous Lymphoma Program, seeks better treatment options for cutaneous T cell lymphoma (CTCL), a rare form of lymphoma that first appears on the skin but can also spread to lymph nodes and internal organs. City of Hope is one of the few institutions in the country that offers clinical trials to treat cutaneous lymphomas. Dr. Querfeld leads a multidisciplinary team of experts, including medical and radiation oncologists, pioneering treatments for CTCL and its subtypes.
Dr. Querfeldâ€™s laboratory investigations are focused on the microenvironment associated with CTCL. She has demonstrated that cancer growth is fostered by the surrounding nonmalignant cells. These observations have led to the initiation of several targeted and immunologic therapies to restore the immune system and hereby killing the cancerous cells. Examples include a microRNA (miR155) antagomir that inhibits proliferation, an anti-CD47 construct enhancing macrophage killing and a randomized investigator initiated trial comparing the checkpoint inhibitor anti-PD-L1 with/without the immunomodulatory drug lenalidomide. Her fundamental laboratory research activities involve dissecting key signaling pathways to advance therapeutic immunologic strategies including mechanisms of resistance.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.
City of Hope is located in Duarte, California, just northeast of Los Angeles, withcommunityclinicsthroughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report . Founded in 1913, City of Hope is a pioneer in the fields ofbonemarrowtransplantation, diabetes and numerous breakthroughcancerdrugsbased on technology developed at the institution.
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability
#Fellow #Dermatology #Cutaneous #Lymphoma #LI-DB1
Meet Some of City of Hope's Employees
Sr Prospect Research Analyst
Working within the Foundation and Relations Department, Libby prepares and provides frontline fundraisers with prospective donor profiles—financing City of Hope’s outstanding patient care and clinical research.
Back to top